"Cost Containment" in the Management of Hypertension

Editorials1 July 1987"Cost Containment" in the Management of HypertensionMARVIN MOSER, M.D.MARVIN MOSER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-107-1-107 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe Direct Cost involved in the treatment of hypertension in the United States has been estimated at approximately $8 billion a year, with more than $1.5 billion being spent on antihypertensive drugs (1). Recent surveys have reported that a significant number of patients with hypertension (20% to 35%) find the cost of drugs to be an obstacle to treatment (2-4). This number has increased during the past 3 to 4 years because newer, more expensive, and heavily promoted drugs have become available. The cost may also have increased further as pressure mounted to use newer forms of technology in the...References1. STASON W. Opportunities for improving the cost-effectiveness of antihypertensive treatment. Am J Med. 1986;81 (suppl 6C):45-9. CrossrefMedlineGoogle Scholar2. SHULMANMARTINEZBROGANCARRMILES NBDAC. Financial cost as an obstacle to hypertension therapy. Am J Public Health. 1986;76:1105-8. CrossrefMedlineGoogle Scholar3. GALLUPCOTUGNO GH. Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med. 1986;81 (suppl 6C) :20-4. CrossrefMedlineGoogle Scholar4. PAULY M. The changing health care environment. AmJMed. 1986;81 (suppl 6C) :3-8. Google Scholar5. MOSER M. A decade of progress in the management of hypertension. Hypertension 1983;5:808-13. CrossrefMedlineGoogle Scholar6. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1977;237:255-61. CrossrefMedlineGoogle Scholar7. The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984;144:1045-57. CrossrefMedlineGoogle Scholar8. CASALEDEVEREUXMILNERZULLOHARSHFIELDPICKERINGLARAGH PRMGGTJ. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-8. LinkGoogle Scholar9. . Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-71. CrossrefMedlineGoogle Scholar10. PICKERING G. High Blood Pressure. New York: Grune & Stratton; 1955. Google Scholar11. HELGELAND A. Treatment of mild hypertension: a five year controlled drug trial: The Oslo Study. Am J Med. 1980;69:725-32. CrossrefMedlineGoogle Scholar12. . Risk factor changes and mortality results. JAMA. 1982;248:1465-77. CrossrefMedlineGoogle Scholar13. MOSER M. Clinical trials, diuretics, and the management of mild hypertension. Arch Intern Med. 1984;144:789-92. CrossrefMedlineGoogle Scholar14. MOSER M. The diuretic dilemma and the management of mild hypertension. J Clin Hypertens. 1986;2:195-202. MedlineGoogle Scholar15. Drug Topics Red Book Update. Oradell; New Jersey: Medical Economics Company; 1986. Google Scholar16. BOCK K. Antihypertension medication costs in the Federal Republic of Germany 1981-1984. In: Proceedings of the 12th Scientific Meeting of the International Society of Hypertension. J Hypertens. 1987. In press. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: MARVIN MOSER, M.D.Affiliations: Yale University School of Medicine New Haven, Connecticut PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPharmacoeconomic Burden of Undertreating HypertensionReserpine: A tragic victim of myths, marketing, and fashionable prescribingImplementation of local guidelines for cost-effective management of hypertensionPrescribing and Drug Costs in the Province of OntarioReserpineDo resident and staff physicians differ in the types and costs of antihypertensive drugs they select?What do you do when the blood pressure is up?The rising expenditure on antihypertensive drugs in New Zealand, 1981–1987Reserpine for HypertensionHypertension Costs: Source, Evolution and Impact of Cost-Containment Measures in Various Health-Care SystemsAmbulatory blood pressure monitoring: Practical considerationsDiabetes, Hypertension and Other Associated DiseasesCorrection: Reserpine DosageLAWRENCE Z. FEIGENBAUM, M.D.The Role of New Antihypertensive DrugsCost Containment and HypertensionLAWRENCE Z. FEIGENBAUM, M.D. 1 July 1987Volume 107, Issue 1Page: 107-109KeywordsDrugsHypertension ePublished: 1 December 2008 Issue Published: 1 July 1987 PDF downloadLoading ...